Journal of Integrative Oncology

Several cutting-edge technologies were being applied in the field of cellular oncology, or the study of cancer at the cellular and molecular level. It's important to note that the field of oncology is constantly evolving and new technologies are continually emerging. Plasma is a component of blood that contains water, electrolytes, hormones, waste products and proteins, According to GLOBOCAN data, 14.1 million new cases and 8.2 million deaths from cancer were estimated in 2012.1 Cancers of the female breast, colorectal, prostate and lung are the most frequently diagnosed cancers in Europe.2 Lung cancer remains the leading cause of cancer incidence and mortality worldwide.

This research project aimed at investigating the role of microRNA 138 (miR-138-5p) in the regulation of pancreatic cancer cell growth and its potential as a therapeutic target. Let's break down the key points: The passage acknowledges the dismal prognosis associated with pancreatic cancer, highlighting that limited progress has been made in its diagnosis and treatment over recent decades. This emphasizes the urgency and importance of research in this area. The primary objective of this study is to understand the role of miR-138-5p in the context of pancreatic cancer. MicroRNAs are small RNA molecules that can influence gene expression and investigating their role in cancer is a common area of research. Pancreatic cancer is indeed one of the most challenging types of cancer, primarily because it is often diagnosed at an advanced stage when treatment options are limited and it has a poor prognosis.

Cancer is a revolutionary approach to treatment that harnesses the body's own immune system to recognize, attack and destroy cancer cells. Unlike traditional cancer treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy works by stimulating or enhancing the body's natural immune response against cancer. The immune system is a complex network of cells, tissues and organs that defends the body against infections and diseases, including cancer. However, cancer cells can sometimes evade detection by the immune system. ver the years, various immunotherapies have been developed and approved for the treatment of different types of cancer. Some of the most notable ones include pembrolizumab and nivolumab (checkpoint inhibitors), as well as CAR T-cell therapies like Kymriah and Yescarta. Immunotherapy has shown remarkable success in treating some types of cancer, leading to long-lasting remissions or even cures in certain patients. It has particularly been effective in melanoma, lung cancer and some forms of leukemia and lymphoma.

Drug resistance is a major challenge in the treatment of cancer. It refers to the ability of cancer cells to survive and continue growing despite exposure to anti-cancer drugs. This uncontrolled growth can result in the formation of a lump or mass called a tumor. These are non-cancerous growths that do not invade nearby tissues or spread to other parts of the body. They tend to grow slowly and are usually not life-threatening. In some cases, cancer cells are inherently resistant to certain drugs. This is known as intrinsic or primary resistance. The genetic makeup of these cells may make them less susceptible to the drug's mechanism of action.